No Data
No Data
HC Wainwright & Co. Downgrades SpringWorks Therapeutics to Neutral, Lowers Price Target to $47
Hold Rating Issued Amid Concerns Over Merck's Acquisition of SpringWorks Therapeutics
TD Cowen Downgrades SpringWorks Therapeutics(SWTX.US) to Hold Rating, Cuts Target Price to $47
Barclays Maintains SpringWorks Therapeutics(SWTX.US) With Hold Rating, Maintains Target Price $47
Guggenheim Downgrades SpringWorks Therapeutics(SWTX.US) to Hold Rating, Cuts Target Price to $47
Guggenheim Downgrades Springworks Therapeutics to Neutral From Buy, Adjusts Price Target to $47 From $77